/ALMS
ALMS Stock - Alumis Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$11.29+2.08%
+$0.23 (+2.08%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+77.1%upside
Target: $19.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALMS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.18 – $11.40
TARGET (TP)$20.00
STOP LOSS$10.39
RISK/REWARD1:9.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.86
52W High$12.44
52W Low$2.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | $-3,152,000 | N/A | $-250,000 |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-300,754,000 | $-158,174,000 | $-113,850,000 |
| Net Income | $-294,233,000 | $-154,993,000 | $-111,930,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-10.38 | $-2.99 | $-14.93 |
Company Overview
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$27
Average Target
↑ 142.5% Upside
Now
$17
Low
$27
Average
$36
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 25th 2025 | Wells Fargo | Initiation | Overweight | $17 |
| June 10th 2025 | Guggenheim | Resumed | Buy | $18 |
| January 30th 2025 | Oppenheimer | Initiation | Outperform | $32 |
| October 31st 2024 | Robert W. Baird | Initiation | Outperform | $25 |
| October 17th 2024 | H.C. Wainwright | Initiation | Buy | $30 |
| July 23rd 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| July 23rd 2024 | Leerink Partners | Initiation | Outperform | $29 |
| July 23rd 2024 | Guggenheim | Initiation | Buy | $32 |
| July 23rd 2024 | Morgan Stanley | Initiation | Overweight | $36 |
Earnings History & Surprises
ALMSBeat Rate
17%
Last 6 quarters
Avg Surprise
-63.3%
EPS vs Estimate
Beats / Misses
1/5
Last 12 quarters
Latest EPS
$-1.06
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
-413.3%
$-23.10vs$-4.50
Q4 24
-5.5%
$-1.73vs$-1.64
Q1 25
+83.6%
$-0.23vs$-1.40
Q2 25
-23.8%
$-1.82vs$-1.47
Q3 25
-5.4%
$-1.17vs$-1.11
Q4 25
-15.2%
$-1.06vs$-0.92
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $-0.90 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.92 | $-1.06 | -15.2% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.11 | $-1.17 | -5.4% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-1.47 | $-1.82 | -23.8% | ✗ MISS |
Q1 2025 | Mar 19, 2025 | $-1.40 | $-0.23 | +83.6% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-1.64 | $-1.73 | -5.5% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-4.50 | $-23.10 | -413.3% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-0.96 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-4.50 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-1.13 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.70 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.69 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Alumis, Raises Price Target to $20
📈 PositiveBenzinga•Dec 18, 2025, 04:26 PM
Alumis Q3 EPS $(1.06) Misses $(0.96) Estimate, Sales $2.066M Miss $2.833M Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:42 PM
Reported Earlier, Apollomics Reverses Wind-Up Plans After $4.1M Funding, Resumes Global Clinical Trials For APL-101 Vebreltinib
📈 PositiveBenzinga•Oct 14, 2025, 04:58 AM
Alumis Misses Q2 Revenue as Costs Jump
📉 NegativeThe Motley Fool•Aug 13, 2025, 08:28 PM
Frequently Asked Questions about ALMS
What is ALMS's current stock price?
Alumis Inc. Common Stock (ALMS) is currently trading at $11.29 per share. The stock has moved +2.08% today.
What is the analyst price target for ALMS?
The average analyst price target for ALMS is $20.00, based on 1 analyst.
What sector is Alumis Inc. Common Stock in?
Alumis Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALMS's market cap?
Alumis Inc. Common Stock has a market capitalization of $1.18 billion, making it a small-cap company.
Does ALMS pay dividends?
No, Alumis Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
ETON
Eton Pharmaceuticals, Inc.
$16.37
Mkt Cap: $0.4B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
LCTX
Lineage Cell Therapeutics, Inc.
$1.68
Mkt Cap: $0.4B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
Explore stocks similar to ALMS for comparison